Bispecific CD20-directed CD3 T Cell Engager [EPC]

4045 reported adverse events

Drugs of this class: EPCORITAMAB-BYSP GLOFITAMAB

These side effects are most commonly reported by patients taking drugs of the Bispecific CD20-directed CD3 T Cell Engager [EPC] class:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 1317
1 DISEASE PROGRESSION 494
2 PYREXIA 369
3 OFF LABEL USE 356
4 DEATH 342
5 DIFFUSE LARGE B-CELL LYMPHOMA 299
6 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 264
7 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 252
8 NEUTROPENIA 227
9 COVID-19 180
See all common reactions for Bispecific CD20-directed CD3 T Cell Engager [EPC]

Drugs of the Bispecific CD20-directed CD3 T Cell Engager [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 252 0.2661
1 B-CELL LYMPHOMA REFRACTORY 12 0.1348
2 FOLLICULAR LYMPHOMA REFRACTORY 7 0.1077
3 TUMOUR FLARE 66 0.0966
4 CYTOKINE RELEASE SYNDROME 1317 0.0656
5 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 264 0.0445
6 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 97 0.0440
7 DIFFUSE LARGE B-CELL LYMPHOMA 299 0.0388
8 COR PULMONALE CHRONIC 7 0.0372
9 INTERLEUKIN-2 RECEPTOR INCREASED 6 0.0351
See all enriched reactions for Bispecific CD20-directed CD3 T Cell Engager [EPC]